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Abstract
The first generation of magnetic resonance conditional pacemakers and implantable
cardioverter-defibrillators has finally arrived in clinical practice after many years of develop-
ment. These devices have been optimized to properly function within magnetic fields of 1.5 T
and ensure safe operation in controlled environments. Further progress is needed to develop
a new generation of magnetic resonance imaging (MRI) conditional devices that can operate in
higher powered MRI machines (3 T) which produce clearer images. (Cardiol J 2012; 19, 1: 98–104)
Key words: magnetic resonance imaging, MRI safety, implantable cardioverter-
-defibrillator, pacemaker
Introduction
Recently, the US Food and Drug Administration
(FDA) and the European Medicines Agency (EMA)
approved the first magnetic resonance imaging
(MRI) conditional pacemakers and implantable car-
dioverter-defibrillators (ICD) designed for use in the
MRI environment under specific conditions [1, 2].
As MRI use increases, so does the number of
patients benefiting from pacemakers and ICDs.
This has resulted in an escalating number of pa-
tients who require magnetic resonance (MR) dia-
gnostic imaging. Approximately 40% of Europeans
and 50–75% of Americans of the more than
1.5 million patients with implanted cardiac devices
may have indications for MRI during the lifetime
of their device (Figs. 1, 2) [3, 4].
Until recently, the presence of pacemakers and
ICDs was considered a contraindication to MR im-
aging due to a variety of safety concerns related to
potential adverse effects on the device from the
strong magnetic and radiofrequency (RF) forces
generated during the scan [5, 6]. These included the
possibility of erratic and inappropriate device func-
tioning during (or after) the scan, over-sensing that
can cause high rate pacing or thermal damage to the
device, and induced voltages on leads that can cause
over- and under-sensing [7]. Moreover, it was
feared that the combined effects would cause com-
ponent failures, mechanical vibration, and device
damage [8–10]. Another reported problem was an
apparent wide variability in response to MRI with
devices of different brands and ages, although there
was some evidence to suggest that newer devices
containing better protective circuitry may be safer
in the setting of MRI. There also was a variability
of effect depending upon the type and duration of
the MRI scan [7].
Serious injury, and even death, have been re-
ported in patients with non conditional pacemakers
and ICDs who have undergone MRI scans [11].
Such events are rare and most reported to date have
occurred during emergency scans in patients who
were not properly prepared or monitored (Fig. 3).
MRIC technology
Patients implanted with pacemakers may re-
quire radiological imaging with MRI for related and
unrelated reasons, such as rotator cuff tears, so the
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Figure 1. Pacemaker and cardioverter-defibrillator (ICD) implants — prevalence of implantable pulse generators (IPG)
and ICDs implanted in the US, 1993–2004 [4].
Figure 2. Magnetic resonance imaging (MRI) procedures — total US MRI procedure volume, hospital and non-
-hospital sites, 1993–2003.
Figure 3. Potential hazard areas for non-conditional implantable cardiac devices in magnetic resonance environment:
B0 — static magnetic field; Gx, Gy and Gz — gravity forces; B1 — radiofrequency signals.
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recent development of MRI-compatible cardiac
implants should be a major help in managing these
patients. The development of magnetic resonance
imaging conditional (MRIC) devices is a logical pro-
gression of the implantable technology. MRIC refers
to the idea that to be used safely in an MRI machine,
a set of specific conditions has to be met regarding
the nature and settings of the magnet [12]. The ef-
fects of the MR environment and MR procedures on
the functional and operational aspects of cardiac pace-
makers and ICDs may vary depending on several fac-
tors, including the type of device, how the device is
programmed, the static magnetic field strength of the
MR system, and the imaging conditions used for the
procedure (i.e. the anatomical region imaged, the type
of transmit RF coil used, the pulse sequence, the
amount of RF energy used, etc.). New MRIC pace-
makers and ICDs have been optimized to function
within magnetic fields of 1.5 T (Tesla) [13, 14]. ‘Tes-
la’ is a measure of the strength of a magnetic field.
The devices are now smaller, made with less
ferrous materials and improved electromagnetic
interference protection [15]. Critical improvements
over older, non MRIC devices include:
1. Elimination of movement of the pulse genera-
tor (can) or lead(s).
2. Preservation of the temporary or permanent
function of the device.
3. Elimination of inappropriate sensing, trigge-
ring, or activation of the device in 1.5 T fields.
4. Elimination of heating of the leads.
5. Elimination of induced currents in the leads.
MRIC device safety
Non-clinical and clinical testing has demon-
strated that the approved pacing systems are safe
for use in the MRI environment when used accord-
ing to the instructions provided by the manufactur-
er [16, 17]. Comprehensive labeling information
must be reviewed and adhered to in order to en-
sure patient safety prior to an MRI scan, which in-
cludes, but is not limited to, MRIC for use [20–22].
A pre-MRI X-ray allows for visual confirmation
of electrode placement and integrity, implantable
pulse generator position, and MR-conditional radio-
paque markers, as shown in Figure 4.
As an example, we review a typical set of MRIC
for the SureScan pacing system [4, 23]:
1. Cylindrical bore magnet, clinical MRI systems
with a static magnetic field of 1.5 T must be used.
2. Gradient systems with a maximum gradient
slew rate performance per axis of less than or
equal to 200 T/m/s must be used.
3. Whole body averaged specific absorption rate
(SAR) as reported by the MRI equipment must be
Figure 4. Right arrow indicates radiopaque emblem of a magnetic resonance-conditional pacemaker. Left arrow
indicates appropriate electrodes or ‘leads’ with magnetic resonance-conditional wavy radiopaque markers [18, 19].
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less than or equal to 2.0 W/kg; head SAR as repor-
ted by the MRI equipment must be < 3.2 W/kg.
4. Patients and their implanted systems must be
screened for the following contraindications:
a. Patients with previously implanted (active
or abandoned) medical devices, leads, lead
extenders, or lead adaptors are contraindi-
cated for an MRI scan.
b. Patients with broken or intermittent leads
are contraindicated for an MRI scan.
c. Patients with a SureScan pacing system that
has been implanted for less than six weeks
are contraindicated for an MRI scan.
d. Patients with a SureScan pacing system im-
planted in sites other than the left and right
pectoral region are contraindicated for an
MRI scan.
e. Patients who do not have a complete Sure-
Scan pacing system, which includes a Sure-
Scan device and both atrial and ventricular
SureScan leads, are contraindicated for an
MRI scan.
f. Patients with pacing capture threshold va-
lues of > 2.0 V at a pulse width of 0.4 ms
are contraindicated for an MRI scan. Note:
Patients experiencing atrial fibrillation may
be scanned if all other pre-MRI scan requ-
irements are satisfied.
g. Patients whose device will be programmed
to an asynchronous pacing mode when MRI
SureScan is on, and who have diaphragma-
tic stimulation at a pacing output of 5.0 V and
at a pulse width of 1.0 ms, are contraindica-
ted for an MRI scan.
h. Patients with a lead impedance value of
< 200 W or > 1,500 W are contraindicated
for an MRI scan.
i. A patient with an implanted SureScan pacing
system must not be positioned on his or her
side within the MRI bore. This position, cal-
led the lateral decubitus position, is contra-
indicated for all MRI scans.
j. The use of local transmit-only coils or local
transmit and receive coils placed directly
over the pacing system has not been studied,
and such use is contraindicated.
5. Continuous patient monitoring must be provided:
a. Preparation for patient rescue. External de-
fibrillator must be available during the MRI
scan.
b. Patient monitoring. During the MRI scan,
the patient’s hemodynamic function must be
continuously monitored using at least one of
the following monitoring systems:
i. electrocardiography
ii. pulse oximetry
iii. non-invasive blood pressure measurement.
Note: If the patient’s hemodynamic function is
compromised during the MRI scan, discontin-
ue the MRI scan and take the proper measures
to restore the patient’s hemodynamic function.
6. The patient must be positioned according to the
contraindications:
a. A patient with an implanted SureScan pacing
system must not be positioned on his or her
side within the MRI bore. This position, cal-
led the lateral decubitus position, is contra-
indicated for all MRI scans.
b. The use of local transmit-only coils or local
transmit and receive coils placed directly
over the pacing system has not been studied,
and such use is contraindicated.
7. There are no patient positioning restrictions
relative to the MRI isocenter landmark when
using the body coil.
8. There are no patient positioning restrictions
relative to the use of any receive-only coils.
9. The implanted system must consist solely of
a SureScan device and SureScan leads. Any other
combination may put the patient at risk during
MRI scans.
Limitations of the MRIC devices
The MRIC systems have some significant limi-
tations, which include the following:
1. The MRIC pacemakers are for new heart pa-
tients only. Patients who already have a pace-
maker cannot get the new models unless they
undergo the risky procedure of having their old
pacemaker completely removed. Usually, when
the time comes to replace the battery in a pa-
cemaker (about 5–7 years), the metal case con-
taining the battery and circuitry is detached
from the leads, and a new model device is ho-
oked up to the leads. But doctors generally
consider it too risky to remove the old leads
from the heart for fear of tearing the heart or
the veins through which the leads are inserted
into the heart. Part of the design of the MRIC
pacemakers involves their new leads, and only
these can be used with new devices [24].
2. Patients must have a new pacemaker implan-
ted for six weeks before receiving an MRI.
3. The MRIC pacemaker requires a certain position
of the patient inside the MRI tube so as to avoid
most chest scans. This is to prevent overheating
the metal tips of the leads that are attached to
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the heart. So, heart scans are forbidden with this
first generation model (En Rhythm, Revo) [4].
4. MRIC will not work for all types of MRI scans
and in all MRI scanners. In addition to the chest
scan exclusion, there is a restriction on how much
RF energy can be deposited into the body by the
scanner. MRI scanners have two operating mo-
des for most clinical applications. ‘Normal ope-
rating mode’ is how the scanner is normally pro-
grammed and that mode restricts the scanner to
lower-energy scans (less than 2 W/kg). This is
sufficient energy for most clinical MRI scans.
However, for some patients and for certain scans,
more power is needed. In these cases, the MRI scan-
ner is placed in ‘First level control’ mode, which al-
lows for greater energy deposition (up to 4 W/kg).
Patients implanted with the Revo MRI pacemaker
are not allowed to have these higher energy scans.
MRIs for these patients are also restricted to only
allow use of 1.5 T MRI systems. Medtronic’s sec-
ond generation MRIC Ensura MRI™ SureScan™
Pacing System (June 2010) and Advisa DR MRI™
SureScan™ pacemaker (March 2010) have no restric-
tions on chest scans [4].
The technical specification and functions of the
MRIC pacemakers listed in Table 1 are available on
the manufacturers’ websites [4, 25, 26] and will not
be discussed here.
First MRIC ICD device
In general, exposure to an MR system or to an
MR procedure has similar effects on an ICD as those
previously discussed for a cardiac pacemaker, since
the devices share the same basic components. How-
ever, there are several unique aspects of ICDs that
impact the possible safe performance of MR proce-
dures in patients with these devices. Therefore,
MRI has been generally contraindicated for patients
with implanted traditional ICDs. All ICDs have also
metallic electrodes placed in the myocardium;
therefore MRI scanning is not advisable with old-
er, non conditional devices due to the inherent risks
related to the presence of these conductive mate-
rials. Although sophisticated scanning algorithms
are proposed for traditional ICDs, their safety re-
mains uncertain.
In November 2011, Biotronik announced the
world’s first MRIC ICD device that directly addressed
the safety issues of ICDs in the MR environment [26].
MRIC ICD — Lumax 740 series device
Lumax 740 series implantable defibrillators
have received European clearance that has con-
firmed them to be MR-compatible when proper pre-
cautions are taken. The series is designed to work
in tandem with Biotronik’s Home Monitoring tech-
nology that can wirelessly transmit critical diagnos-
tic data from the implant to the patient’s physician
or monitoring center. Biotronik has reported that
following the approval, initial implantations of the
devices were performed.
A brief device description from the manufac-
turer’s announcement:
The new Lumax 740 series is part of Biotro-
nik’s technologically advanced tachycardia product
portfolio, which includes three ICDs, one CRT-D
device and 16 leads. The Linoxsmart ICD leads have
been proven over time to be of the highest quality
and reliability, and are now further enhanced with
ProMRI® compatibility. Besides featuring ProMRI®
technology, the devices also stand out in the indus-
try by providing longevity of up to 11 years.
Additionally, the intracardiac impedance mea-
sure is being used to investigate changes in left
ventricular volume as a parameter that could poten-
tially be taken for optimizing cardiac resynchroni-
zation therapy (CRT) and predicting worsening
heart failure. This data is transmitted from the pa-
tient’s device to the physician continuously and
automatically using Biotronik Home Monitoring®,
Table 1. Availability of approved magnetic resonance imaging conditional devices.
Device Type Availability date Region
EnRhythm MRI SureScan (Medtronic, Inc.) Pacemaker 2008 Europe
Accent MRI (St. Jude Medical Inc.) Pacemaker 2010 Europe
ProMRI (Biotronik) Pacemaker 2010 Europe
Ensura MRI SureScan (Medtronic, Inc.) Pacemaker 2010 Europe
Advisa DR MRI SureScan (Medtronic, Inc.) Pacemaker 2010 Europe
Revo MRI SureScan Pacemaker System (Medtronic, Inc.) Pacemaker  2011 USA
Lumax 740 series Device (Biotronik) ICD 2011 Europe
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the industry’s only remote patient management
system that is FDA and EMA approved for the ear-
ly detection of clinically relevant events.
Regulatory status of MRIC
Medtronic is the first supplier to gain FDA
approval for the MR-conditional device. Medtronic’s
Revo MRI™ SureScanR Pacing System (Model#:
RVDR01) received FDA approval on 8 February,
2011. Medtronic’s Ensura MRI™ SureScan™ Pa-
cing System (June 2010) and Advisa DR MRI™
SureScan™ pacemaker (March 2010) have been
approved for use outside the United States [4]. Both
devices have labeling with no restrictions on chest
scans. St. Jude Medical Inc. Accent MRI MR-con-
ditional pacemaker 25 has also been approved for
use outside the United States. Biotronik’s Lumax
740 ICD is available in Europe [26].
Clinical research summary
There are several ongoing clinical trials cen-
tered on MRIC devices [27, 28]:
The MagnaSafe Registry
• Device: ALL
• Company: ALL
• Dr. R.J. Russo (United States) (Principal Inve-
stigator) (Scripps Clinic/Green)
• N = 1,500 patients
• Status: Enrolling (since April 2009)
• Multi-center, observational registry
This investigator-initiated study is designed to de-
termine the risks of performing MRI for patients
with pacemakers and ICDs. The goal is to provide
physicians with the risk-assessment data needed to
determine the use of MRI as a diagnostic tool when
no alternative diagnostic imaging technology is ap-
propriate.
Advisa MRI Study
• Device: Advisa DR MRI™ Pacing System
• Company: Medtronic
• Medtronic Advisa MRI Lead (United States)
(Principal Investigator)
• N = 270 patients
• Status: Enrolling (since June 2010)
• Allocated, randomized, multi-center U.S. trial
This clinical study is designed to confirm the safe-
ty and effectiveness of the Advisa DR MRI pacing
system in the clinical MRI environment. The de-
vice will be studied with MRI scans up to 2 W/kg
SAR without positioning restrictions. Enrollment
was scheduled to be completed by October 2011.
Accent MRI Study
• Device: Accent MRI™ Pacemaker System
• Company: St. Jude Medical
• St. Jude Lead (United States) (Principal Investi-
gator)
• N = 60 patients
• Status: Enrolling (since January 2011)
• Prospective, observational, single-center study.
This Accent MRI study is designed to evaluate the
performance of the implanted Accent MRI™ pacing
system in a clinical setting and optionally in the MRI
environment. The pacer will include the Tendril
MRI™ lead as well as the MRI Activator™. The
study goal is to prove the safety and efficacy of the
system. Enrollment is scheduled for completion by
January 2012.
Clinically indicated magnetic resonance
imaging in patients with cardiac devices
• Device: Revo MRI pacing system
• Company: Medtronic
• Dr. H.R. Halperin (United States) (Principal In-
vestigator) (Johns Hopkins University) (UHC)
• N = 1,000 patients
• Status: Enrolling (since May 2010)
• Prospective, observational, single-center study.
This prospective cohort study is designed to use an
established MRI device safety protocol to decrease
the risk of clinically indicated MR imaging in pa-
tients who have implantable cardiac devices.
Conclusions
MRIC technology for implantable cardiac de-
vices has arrived. It has the potential to change
clinical practice and significantly increase hospi-
tal costs. At the present time it is limited to 1.5 T
scanners for safety reasons. Right now, the issue
is that MRIC devices are designed only for 1.5 T
powered MRI systems and the trend is to move to
higher powered MRI machines (3 T), which pro-
duce clearer images in less time and for which the
present devices are not indicated [27]. In the fore-
seeable future, all pacemakers and ICDs should be
MRI-compatible and we believe they will be. So it
seems to have been a good start for MRIC techno-
logy, but there is plenty of technical development
still to go.
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